Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 6, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to...
-
Nov 9, 2021Enrolled first patient in Phase 1 Study of CA-4948 combination therapy in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter...
-
Nov 9, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a poster presentation with new preclinical...
-
Nov 8, 2021- Initial data expected in 2022 -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the...
-
Nov 2, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third...
-
Nov 2, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that Curis management will participate in...
-
Oct 7, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical...
-
Oct 6, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2021, the independent...
-
Sep 2, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
-
Aug 3, 2021- Presented positive updated data from Phase 1/2 study of CA-4948 monotherapy in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA) -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended